|
|
11/4/2004 9:22:03 AM ET News Release Index
SWISS MEDICA’S RECENT SALES ORDERS CONFIRM SUCCESSFUL O24 PRODUCT LAUNCH
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
November 4, 2004
SWISS MEDICA’S RECENT SALES ORDERS CONFIRM SUCCESSFUL O24 PRODUCT LAUNCH
Toronto, Canada – Early fourth quarter sales orders, through November 2nd, confirm the success of the retail
launch for Swiss Medica’s O24™ Essential Oil Pain Neutralizer. Sales orders have nearly matched the entire
revenues for the Company’s third quarter, which were approximately US$238,000. Third quarter financial results
will be included in the Company’s 10-Q, which will be filed with the U.S. Securities and Exchange Commission by
November 15th.
“Our team is now executing the detailed marketing programs earlier announced in the Company’s news releases
of July 12, August 26 and September 29, 2004,” Chief Executive Officer, Raghu Kilambi stated. “Fourth quarter
sales orders currently stand at approximately US$230,000 and will be recognized as revenues in the fourth
quarter. This is the best start to any quarter in the Company’s history and reflects only about one month of
orders.”
The orders are comprised of substantial and multiple re-orders from pharmacy and natural retailers, initial orders
from new retailers, rapidly escalating online sales, and Swiss Medica’s first U.S. order from a highly visible
regional pharmacy chain within a multi-state locus that includes at least three major U.S. cities.
“Our marketing efforts during the first eight weeks of our launch have been reflected in the website traffic for our
store locators, a place where consumers can not only directly order the O24™ Essential Oil Pain Neutralizer, but
also where many search to find the nearest retailer in their neighborhood,” said Grant Johnson, Swiss Medica’s
President and Chief Operating Officer. “Website traffic during October was more than double that of our strong
August showing and jumped by more than 53% over September’s high-traffic month. Clearly, we anticipate fourth
quarter online traffic to double over the third quarter.”
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be a
world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
visit our websites at www.swissmedica.com and www.024zone.com
Swiss Medica’s flagship product, the 024™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The
024™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits
by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout
Canada in leading pharmacies and natural food stores. It is available in the United States and elsewhere by
visiting www.024zone.com, for ordering details and store locators.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
Investor Relations Contact:
|
|
